Generate actionable intelligence on the scientific, clinical, and competitive landscape for next-generation sequencing and other molecular diagnostic tests used in oncology.
Responsibilities
Critically evaluate publications, clinical trials, validation studies, and congress presentations to assess assay performance, clinical validity, clinical utility, and relevance to patient care.
Analyze developments in comprehensive genomic profiling, tissue and liquid biopsy, companion diagnostics, molecular residual disease testing, and emerging early detection approaches.
Compare study designs, patient populations, endpoints, and methodological limitations to determine the strength of evidence supporting diagnostic claims.
Monitor oncology testing guidelines and clinical practice developments that may affect test adoption, evidence requirements, or product positioning.
Track competitor test launches, product enhancements, regulatory activity, partnerships, pricing, reimbursement, and commercial developments.
Requirements
Bachelor's degree in life sciences, molecular biology, genetics, or a related field
Nice to have: Advanced degree in a relevant scientific or clinical discipline
Nice to have: Experience in a molecular diagnostics laboratory
Nice to have: Familiarity with diagnostic regulatory pathways
Nice to have: Experience conducting expert interviews or developing scientific and competitive congress summaries
The BA Senior Manager owns discrete commercial assessments and forecasts end to end — building the model, framing the assumptions, and defending both — to inform investment decisions, partnering with colleagues across Research & Development, Global Commercial Strategy, the US and International commercial organizations, and Business Development (BD) to objectively evaluate internal pipeline and external opportunities against strategy and investment criteria.
Compensation
annual base salary for this position ranges from $124,400 to $207,000... bonus target of 15% of base
Responsibilities
Build and own assessments of pipeline and BD opportunities — including epidemiology-based patient flow, treatment exposure, uptake and diffusion curves, gross-to-net price build, and risk-adjusted NPV
Take and defend an independent position — including recommending against an opportunity when the analysis does not support it
Gather input from key internal expert stakeholders on the potential clinical development plan or commercial evaluation
Integrate in-line and BD/pipeline forecasts - connect BD/pipeline assessments to in-line assumptions, cannibalization logic, and Long-Range Forecast (LRF) revenue projections
AI-enabled assessment - use AI tooling as a standard part of the workflow: evidence and literature synthesis, competitive landscaping, model QC and error-checking, code-assisted analysis, and drafting of executive materials